Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this clinical trial is to evaluate the safety and efficacy of rhEGF (recombinant human Epidermal Growth Factor) in diabetic foot ulcer patients with uncontrolled diabetes mellitus.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| rhEGF(recombinant human Epidermal Growth Factor) | Experimental | BID |
|
| placebo | Placebo Comparator | BID |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| rhEGF(recombinant human Epidermal Growth Factor) | Drug |
| ||
| placebo of rhEGF(recombinant human Epidermal Growth Factor) |
| Measure | Description | Time Frame |
|---|---|---|
| At 12 weeks, wound closure rate of diabetic foot ulcers | 12 weeks from the start day of treatment (But, the study can be finished before 12 weeks) |
| Measure | Description | Time Frame |
|---|---|---|
| Time to reach complete wound closure | 12weeks | |
| average size reduction of diabetic ulcer | 12 week |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| College of Medicine, Yonsei University | Seoul | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
|